Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
The latest trial study from Savara Inc (NASDAQ:SVRA) met its primary endpoint.
賽諾菲安萬特公司的最新試驗研究達成了主要終點。
The company released results from Phase 3 IMPALA-2 trial of molgramostim 300 mcg administered once daily by inhalation with a matching placebo for autoimmune pulmonary alveolar proteinosis (aPAP).
該公司發佈了molgramostim 300 mcg一日一次通過吸入與配對安慰劑治療自身免疫性肺泡蛋白症（aPAP）的3期IMPALA-2試驗結果。
Matt Pauls, CEO Savara, praised the results.
賽伐拉公司的首席執行官馬特·保羅斯稱讚了這一結果。
PAP is a rare lung disease caused by a buildup of proteins, fats, and other substances in the lungs' air sacs (alveoli).
肺泡蛋白症（PAP）是一種罕見的肺部疾病，由於肺泡（肺部的小氣囊）內蛋白質、脂肪和其他物質積聚引起。
Molgramostim is an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).
Molgramostim是重組人粒細胞巨噬細胞集落刺激因子（GM-CSF）的吸入劑型。
The treatment difference between molgramostim and placebo for mean change from baseline to Week 24 in hemoglobin-adjusted percent predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) achieved statistical significance, with a change of 6%.
molgramostim與安慰劑相比，在24周時從基線到肺一氧化碳彌散能力的均值變化上達到了統計學顯著性，變化率爲6%。
The DLCO test measures how much carbon monoxide passes from your lungs to the blood.
DLCO測試測量從肺到血液中一氧化碳的通過量。
This statistically significant treatment difference was sustained at Week 48, a secondary endpoint, with a change of 6.90%, demonstrating the durability of the effect.
這種具有統計學顯著性的治療差異在第48周得到了維持，變化率爲6.90%，證明了該效果的持久性。
The treatment difference between molgramostim and placebo for mean change from baseline to Week 24 in St. George's Respiratory Questionnaire Total Score (SGRQ) achieved statistical significance.
在基線到第24周的平均變化方面，molgramostim和安慰劑的治療差異爲聖喬治呼吸問卷總得分（SGRQ）在24周時達到了統計學顯著性。SGRQ是一種標準化的自行完成問卷，用於測量氣道疾病中的健康障礙和感知的幸福感（'生活質量'）。從基線開始的負面變化對應於改善。
SGRQ is a standardized self-completed questionnaire measuring impaired health and perceived well-being ('quality of life') in airway disease. A negative change from baseline corresponds to improvement.
SGRQ是一份標準的自我評估調查問卷，用於測量呼吸道疾病患者的健康受損和感知的幸福程度（“生活質量”）。基線變化的負數對應改善。
The SGRQ total score at 24 weeks was -6.59 and -4.87 at 48 weeks.
24周時的SGRQ總得分爲-6.59，48周時爲-4.87。
Two additional secondary endpoints reached nominal significance: SGRQ Activity Score at Week 24 and exercise capacity using a treadmill test at Week 48.
兩個額外的二級終點結果達到了名義顯著性：24周的SGRQ活動評分和48周的跑步機測試的運動能力。
SGRQ Activity assesses the patient's ability to carry out daily physical activity.
SGRQ活動評估患者進行日常體育活動的能力。24周時的SGRQ活動評分爲-7.81，48周時爲-5.99。
SGRQ Activity Score at 24 weeks was -7.81 and -5.99 at 48 weeks.
24周時的SGRQ活動得分爲-7.81，在48周時爲-5.99。
Molgramostim was well tolerated. The frequency of adverse events was generally similar between treatment groups.
molgramostim耐受性良好。不良事件的發生頻率在治療組之間普遍相似。有2名患者（2.5%）因不良事件停止了molgramostim治療，這兩個事件都被認爲與試驗藥物無關。
Two patients (2.5%) discontinued molgramostim treatment due to adverse events, both of which were considered unrelated to the trial drug.
兩名患者（2.5％）因不良事件而停止molgramostim治療，這兩種不良事件都被認爲與試驗藥物無關。
Price Action: SVRA shares are up 30% at $4.94 during the premarket session at last check Wednesday.
SVRA股票在週三盤前交易階段上漲30%，最後報4.94美元。
Now Read: Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
現在閱讀：賽諾菲尋求賣出價值200億美元的Icy Hot部門：可能的競標者包括Advent、PAI Partners、黑石、CVC。
譯文內容由第三人軟體翻譯。